In vivo metabolism of a new anticancer agent, 6-N-formylamino-12,13- dihydro-1,11-dihydroxy-13-(β-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4- c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: Pharmacokinetics, isolation, identification, and quantification of metabolites

Drug Metabolism and Disposition

Volumn 27, Issue 2, 1999, Pages 205-212

  Takenaga, N ^a   Ishii, M ^a   Nakajima, S ^a   Hasegawa, T ^a   Iwasa, R ^a   Ishizaki, H ^a   Kamei, T ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; RBM 1; RBM 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BILE; BIOTRANSFORMATION; CARBAZOLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA TOPOISOMERASES, TYPE I; DOGS; ENZYME INHIBITORS; GLUCOSIDES; HALF-LIFE; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; CANIS FAMILIARIS;

EID: 0032936689     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Arakawa H, Iguchi T, Morita M, Yoshinari T, Kojiri K, Suda H, Okura A and Nishimura S (1995) Novel indolecarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosil)-5H- indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7(6H)-dione (NB-506): Its potent antitumor activities in mice. Cancer Res 55:1316-1320.
2. Collins JM, Grieshaber CK and Chabner BA (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82:1321-1326.
3. European Organization for Research and Treatment of Cancer (EORTC) Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur J Cancer & Clin Oncol 23:1083-1087.
4. Gibaldi M and Perrier D (1982) Noncompartmental analysis based on statistical moment theory, in Pharmacokinetics (Swarbrick J ed) pp 409-418, Marcel Dekker, New York.
5. Graham MA and Workman P (1992) The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: Critical evaluation and recommendations for future studies. Ann Oncol 3:339-347.
6. 14C]NB-506 after single and repeated intravenous administration in rats. Xenobio Metabol and Dispos 13:337-345.
7. Lin JH, Sugiyama Y, Awazu S and Hanano M (1982) Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm 10:649-661.
8. Lin JH, Chiba M, Balani SK, Chen I-Wu, Kwei GYS, Vastag KJ and Nishime J (1996) Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immuno-deficiency virus protease inhibitor. Drug Metab Dispos 24:1111-1120.
9. Ludden TM (1991) Nonlinear pharmacokinetics: Clinical implications. Clin Pharmacokinetic 20:429-446.
10. Mordenti J (1986) Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1040.
11. Sasaki Y, Tanigawara Y, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K, Ogino H, Takenaga N, Okada K, Nishimura S and Abe K (1995) Phase I and pharmacology study of NB-506. ASCO Proc 14:172.
12. Sathirakul K, Suzuki H, Yamada T, Hanano M and Sugiyama Y (1994) Multiple transport systems for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 268:65-73.
13. Shimamura H, Suzuki H, Hanano M, Suzuki A, Tagaya T, Horie T and Sugiyama Y (1994) Multiple systems for the biliary excretion of organic anions in rats: Liquiritigenin conjugates as model compounds. J Pharmacol Exp Ther 271:370-378.
14. Takenaga N, Ishii Y, Monden S, Sasaki Y and Hata S (1995) Simultaneous determination of a new anticancer agent (NB-506) and its active metabolite in human plasma and urine by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 674:111-117.
15. Yamazaki M, Akiyama S, Niinuma K, Nishigaki R and Sugiyama Y (1997) Biliary excretion of pravastatin in rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 25:1123-1129.
16. Yoshinari T, Matsumoto M, Arakawa H, Okada H, Noguchi K, Suda H, Okura A and Nishimura S (1995) Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosil)-5H- indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7(6H)-dione (NB-506): Induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res 55:1310-1315.